AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Usynova Pharmaceuticals Ltd. logo
Usynova Pharmaceuticals Ltd.Private
1 asset: 1 Ph 1UA026Phase 1 · PsoriasisNone on record————
Uvax Bio logo
Uvax BioPrivate
1 asset: 1 Ph 1UVAX-1107Phase 1 · HIVNone on record————
Valo Therapeutics Oy logo
Valo Therapeutics OyPrivate
1 asset: 1 Ph 1PeptiCRAd-1Phase 1 · Non-Small Cell Lung Cancer30 Apr 2027PeptiCRAd-1 · Phase 1————
V
Valorum Biologics LLCPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Vantive Health logo
Vantive HealthPrivate
1 asset: 1 Ph 3Icodextrin (peritoneal ultrafiltration)Phase 3 · Heart FailureWeak signalNone on record————
Vasa Therapeutics logo
Vasa TherapeuticsPrivate
1 asset: 1 Ph 1Vasa Therapeutics VS-041Phase 1 · Heart FailureNov 2026Vasa Therapeutics VS-041 · Phase 1————
Vascarta Inc. logo
Vascarta Inc.Private
1 asset: 1 Ph 1VAS-101Phase 1 · Sickle Cell DiseaseNone on record————
Vaxine Pty Ltd logo
Vaxine Pty LtdPrivate
1 asset: 1 Ph 2HepadvaxPhase 1/2 · Chronic Hepatitis B1 Mar 2027Hepadvax · Phase 1/2————
Ventrix logo
VentrixPrivate
1 asset: 1 Ph 1VentriGelPhase 1 · Heart FailureWeak signalNone on record————
Ventus Therapeutics U.S., Inc. logo
Ventus Therapeutics U.S., Inc.Private
1 asset: 1 Ph 2VENT-03Phase 2 · Systemic Lupus ErythematosusDec 2026VENT-03 · Phase 2————
Verdiva Bio logo
Verdiva BioPrivate
1 asset: 1 Ph 2Ecnoglutide (VRB-101)Phase 2 · ObesityPartial signal5 Jan 2027Ecnoglutide (VRB-101) · Phase 1/2————
Verity Pharma logo
Verity PharmaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
V
VERO BiotechPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Vertero Therapeutics logo
Vertero TherapeuticsPrivate
1 asset: 1 Ph 1VT-5006Phase 1 · Parkinson's DiseaseNone on record————
Verve Therapeutics logo
Verve TherapeuticsPrivate
2 assets: 1 Ph 2, 1 Ph 1VERVE-102Phase 2 · Atherosclerotic Cardiovascular DiseaseDec 2027VERVE-201 · Phase 1—$502MMar 2025~16.2 qtrs$210M
V
Vifor Fresenius Medical Care Renal PharmaPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Vifor Pharma logo
Vifor PharmaPrivate
7 assets: 5 approved, 1 Ph 3, 1 Ph 2PatiromerPhase 3 · Chronic Kidney DiseasePartial signalMar 2027sparsentan · Approved————
ViiV Healthcare logo
ViiV HealthcarePrivate
10 assets: 5 approved, 4 Ph 2, 1 Ph 1DezecapavirPhase 2 · HIVPartial signal22 Jan 2027Fostemsavir · Phase 1————
Vimgreen Pharmaceuticals logo
Vimgreen PharmaceuticalsPrivate
1 asset: 1 Ph 3VG081821ACPhase 2/3 · Parkinson's Disease1 Oct 2027VG081821AC · Phase 2/3————
Vincentage Pharma logo
Vincentage PharmaPrivate
1 asset: 1 Ph 3VCT220Phase 3 · ObesityReliable signal1 Jul 2027VCT220 · Phase 2————
Viriom logo
ViriomPrivate
1 asset: 1 Ph 3ElsulfavirinePhase 2/3 · HIVPartial signalNone on record————
V
Virogenics, Inc.Private
1 asset: 1 Ph 1CMS121Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
Vitrac Therapeutics, LLC logo
Vitrac Therapeutics, LLCPrivate
1 asset: 1 Ph 1VIC-1911Phase 1 · Non-Small Cell Lung CancerWeak signalNone on record————
Vivace Therapeutics, Inc logo
Vivace Therapeutics, IncPrivate
1 asset: 1 Ph 2VT3989Phase 1/2 · Non-Small Cell Lung Cancer1 May 2028VT3989 · Phase 3————
VivaCell Biotechnology España logo
VivaCell Biotechnology EspañaPrivate
1 asset: 1 Ph 2EtribnabdionePhase 2 · Atherosclerotic Cardiovascular DiseaseMar 2027Etribnabdione · Phase 2————
VIVUS logo
VIVUSPrivate
2 assets: 1 approved, 1 Ph 3Extended-release tacrolimus (VI-0106)Phase 3 · Pulmonary Arterial Hypertension31 May 2028Extended-release tacrolimus (VI-0106) · Phase 3————
VM Discovery, Inc. logo
VM Discovery, Inc.Private
1 asset: 1 Ph 2VMD-102Phase 1/2 · Non-Small Cell Lung CancerMay 2031VMD-102 · Phase 1/2————
VM Oncology, LLC logo
VM Oncology, LLCPrivate
1 asset: 1 Ph 2VMD-928Phase 1/2 · Non-Small Cell Lung CancerDec 2027VMD-928 · Phase 1/2————
Volastra Therapeutics, Inc. logo
Volastra Therapeutics, Inc.Private
1 asset: 1 Ph 2OrvanesibPhase 1/2 · Non-Small Cell Lung CancerNone on record————
V
VRisePrivate
1 asset: 1 Ph 2KQ-2003Phase 1/2 · Multiple MyelomaWeak signal31 Dec 2027KQ-2003 · Phase 1————
VTBIO Co. Ltd (South Korea) logo
VTBIO Co. Ltd (South Korea)Private
1 asset: 1 Ph 1VT301Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
Vyriad, Inc. logo
Vyriad, Inc.Private
1 asset: 1 Ph 2VSV-IFNβ-NISPhase 2 · MelanomaNone on record————
W
Waylis Therapeutics LLCPrivate
4 assets: 4 approvedApproved assets onlyNone on record————
W
Welichem BiotechPrivate
1 asset: 1 approvedApproved assets onlyAug 2027Tapinarof · Phase 3————
Windward Bio logo
Windward BioPrivate
1 asset: 1 Ph 3WIN378Phase 2/3 · AsthmaWeak signal17 Dec 2027WIN378 · Phase 2————
W
WinHealth PharmaPrivate
1 asset: 1 approvedApproved assets only15 Aug 2029Difelikefalin · Phase 2————
WinSanTor logo
WinSanTorPrivate
1 asset: 1 Ph 2Pirenzepine (topical)Phase 2 · Diabetic Peripheral Neuropathic PainPartial signalNone on record————
W
Wondercel Biotech (Shenzhen) Co., Ltd.Private
1 asset: 1 Ph 1UWD-00BPhase 1 · Multiple MyelomaNone on record————
Wuhan Createrna Science and Technology logo
Wuhan Createrna Science and TechnologyPrivate
1 asset: 1 Ph 3QR12000Phase 3 · HypertensionPartial signalNone on record————
Xantho Biotechnology logo
Xantho BiotechnologyPrivate
1 asset: 1 Ph 2GM-XANTHOPhase 2 · PsoriasisPartial signal31 Dec 2027GM-XANTHO · Phase 2————
Xcovery Holdings logo
Xcovery HoldingsPrivate
1 asset: 1 approvedApproved assets only1 Feb 2029Ensartinib · Phase 1/2————
XellSmart Bio-Pharmaceutical (Suzhou) logo
XellSmart Bio-Pharmaceutical (Suzhou)Private
1 asset: 1 Ph 2XS-411Phase 1/2 · Parkinson's Disease30 Mar 2028XS-411 · Phase 1/2————
X
Xinjiang Uygur PharmaceuticalPrivate
1 asset: 1 otherYangxin Dawayimixike Honey PasteAtherosclerotic Cardiovascular DiseaseJul 2028Yangxin Dawayimixike Honey Paste · Approved————
XYone Therapeutics, Inc logo
XYone Therapeutics, IncPrivate
1 asset: 1 Ph 2XYA02Phase 1/2 · Non-Small Cell Lung Cancer15 Sep 2029XYA02 · Phase 1/2————
Yabao Pharmaceutical Group logo
Yabao Pharmaceutical GroupPrivate
1 asset: 1 Ph 2Globalagliatin HydrochloridePhase 2 · Type 2 DiabetesPartial signalNone on record————
Y
Yangli Pharmaceutical TechnologyPrivate
1 asset: 1 Ph 2VB19055Phase 2 · HypertensionDec 2027VB19055 · Phase 2————
Y
Yaso TherapeuticsPrivate
1 asset: 1 otherYASO GELHIVFeb 2028YASO GEL · Phase 1————
Zambon SpA logo
Zambon SpAPrivate
3 assets: 2 approved, 1 Ph 1Voriconazole (ZP-059)Phase 1 · AsthmaWeak signalNone on record————
Zensun (Shanghai) Sci & Tech logo
Zensun (Shanghai) Sci & TechPrivate
1 asset: 1 Ph 3Recombinant human neuregulin-1 (rhNRG-1)Phase 3 · Heart FailurePartial signalNone on record————
Zenyaku Kogyo logo
Zenyaku KogyoPrivate
1 asset: 1 approvedApproved assets only1 Dec 2026Rituximab · Phase 2————
Zhejiang Carbiogene Therapeutics Co., Ltd. logo
Zhejiang Carbiogene Therapeutics Co., Ltd.Private
1 asset: 1 Ph 1CBG002Phase 1 · Multiple Myeloma25 Oct 2027CBG002 · Phase 1————
Zhejiang Doer Biologics logo
Zhejiang Doer BiologicsPrivate
1 asset: 1 Ph 3DR10624Phase 3 · Severe HypertriglyceridemiaPartial signalApr 2028DR10624 · Phase 2—$15.7BJun 2026~18.0 qtrs~$2.4B
Zhejiang Kanova Biopharmaceutical logo
Zhejiang Kanova BiopharmaceuticalPrivate
1 asset: 1 Ph 2XKH001Phase 2 · Atopic Dermatitis1 Apr 2027XKH001 · Phase 1————
Z
Zhejiang Palo Alto Pharmaceuticals, Inc.Private
1 asset: 1 Ph 2PA1010Phase 1/2 · Chronic Hepatitis BNone on record————
Z
Zhimeng BiopharmaPrivate
2 assets: 1 Ph 3, 1 Ph 1CB03-154Phase 2/3 · Amyotrophic Lateral SclerosisSep 2027CB03-154 · Phase 2————
Zhiyi Pharmaceutics logo
Zhiyi PharmaceuticsPrivate
1 asset: 1 Ph 2Live SK08Phase 2 · Ulcerative ColitisNone on record————
Zumutor Biologics Inc. logo
Zumutor Biologics Inc.Private
1 asset: 1 Ph 1ZM008Phase 1 · Non-Small Cell Lung CancerDec 2026ZM008 · Phase 1————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415